Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference
Windtree Therapeutics, Inc. (WINT)
Last windtree therapeutics, inc. earnings: 8/21 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
windtreetx.investorroom.com
Company Research
Source: GlobeNewswire
WARRINGTON, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced istaroxime data from the early cardiogenic shock SEISMiC Extension Phase 2b study will be presented today at the European Society of Cardiology Heart Failure 2025 Conference in Belgrade, Serbia. The istaroxime data will be presented by Jan Biegus MD, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland. The presentation is entitled, “Safety and Efficacy of up to 60 Hours of Intravenous Istaroxime for Patients with Pre-Cardiogenic Shock: the SEISMiC Trial.” “The positive results from the SEISMiC Extension Study are important data to help us advance istaroxime toward Phase 3 for cardiogenic shock,” said Dr. Steve Simonson, Chief Medical Officer and Senior Vice
Show less
Read more
Impact Snapshot
Event Time:
WINT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WINT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WINT alerts
High impacting Windtree Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
WINT
News
- Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates [Yahoo! Finance]Yahoo! Finance
- Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug CandidatesGlobeNewswire
- Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech SpaceGlobeNewswire
- Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee [Yahoo! Finance]Yahoo! Finance
- Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the LicenseeGlobeNewswire
WINT
Sec Filings
- 12/2/25 - Form 8-K
- 11/21/25 - Form 424B3
- 11/19/25 - Form 10-Q
- WINT's page on the SEC website